moxifloxacin has been researched along with dihydroergotamine in 4 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (dihydroergotamine) | Trials (dihydroergotamine) | Recent Studies (post-2010) (dihydroergotamine) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 1,450 | 241 | 116 |
| Protein | Taxonomy | moxifloxacin (IC50) | dihydroergotamine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.09 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 3.9996 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.001 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0089 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0039 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.01 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.0007 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 2.395 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.029 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.008 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.09 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.0007 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.0053 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.0068 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.0032 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 2.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
| Haugen, G; Kellerman, DJ; Kori, S; Voloshko, P | 1 |
1 review(s) available for moxifloxacin and dihydroergotamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for moxifloxacin and dihydroergotamine
| Article | Year |
|---|---|
Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers.
Topics: Administration, Inhalation; Adult; Aza Compounds; Cross-Over Studies; Dihydroergotamine; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Quinolines; Vasoconstrictor Agents; Young Adult | 2012 |
2 other study(ies) available for moxifloxacin and dihydroergotamine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |